These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 20136418)

  • 1. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study.
    Artunay O; Yuzbasioglu E; Rasier R; Sengul A; Bahcecioglu H
    Curr Eye Res; 2010 Feb; 35(2):91-8. PubMed ID: 20136418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal bevacizumab injection for central serous chorioretinopathy.
    Lim SJ; Roh MI; Kwon OW
    Retina; 2010 Jan; 30(1):100-6. PubMed ID: 20010322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal bevacizumab injection for central serous chorioretinopathy.
    Chhablani JK; Narayanan R
    Retina; 2010 Sep; 30(8):1323-24; author reply 1324. PubMed ID: 20661171
    [No Abstract]   [Full Text] [Related]  

  • 4. Intravitreal bevacizumab injection for central serous chorioretinopathy.
    Nowroozzadeh MH
    Retina; 2010 Sep; 30(8):1322-3; author reply 1323. PubMed ID: 20827148
    [No Abstract]   [Full Text] [Related]  

  • 5. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.
    Chan WM; Lai TY; Liu DT; Lam DS
    Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of one-year follow-up examinations after intravitreal bevacizumab administration for chronic central serous chorioretinopathy.
    Inoue M; Kadonosono K; Watanabe Y; Kobayashi S; Yamane S; Arakawa A
    Ophthalmologica; 2011; 225(1):37-40. PubMed ID: 20693820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short-term effect.
    Seong HK; Bae JH; Kim ES; Han JR; Nam WH; Kim HK
    Ophthalmologica; 2009; 223(5):343-7. PubMed ID: 19521133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia.
    Charbel Issa P; Holz FG; Scholl HP
    Ophthalmology; 2007 Sep; 114(9):1736-42. PubMed ID: 17822979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
    Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
    Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal bevacizumab as primary treatment for retinal angiomatous proliferation: twelve-month results.
    Gharbiya M; Allievi F; Recupero V; Martini D; Mazzeo L; Gabrieli CB
    Retina; 2009 Jun; 29(6):740-9. PubMed ID: 19516116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal bevacizumab in the management of subretinal fluid associated with choroidal osteoma.
    Song JH; Bae JH; Rho MI; Lee SC
    Retina; 2010 Jun; 30(6):945-51. PubMed ID: 20531145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of 1-year follow-up examinations after intravitreal bevacizumab administration for idiopathic choroidal neovascularization.
    Inoue M; Kadonosono K; Watanabe Y; Sato S; Kobayashi S; Yamane S; Ito R; Arakawa A
    Retina; 2010 May; 30(5):733-8. PubMed ID: 20168271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: six-month results of a prospective pilot study.
    Chan WM; Lai TY; Liu DT; Lam DS
    Ophthalmology; 2007 Dec; 114(12):2190-6. PubMed ID: 17599414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
    Ding X; Li J; Hu X; Yu S; Pan J; Tang S
    Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.
    Wu L; Arevalo JF; Roca JA; Maia M; Berrocal MH; Rodriguez FJ; Evans T; Costa RA; Cardillo J;
    Retina; 2008 Feb; 28(2):212-9. PubMed ID: 18301025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Recurrent and chronic central serous chorioretinopathy. Retina thickness evaluation one month after intravitreal bevacizumab injection].
    Gregori-Gisbert I; Aguirre-Balsalobre F; García-Sánchez J; León-Salvatierra G; Mengual-Verdú E; Hueso-Abancéns JR
    Arch Soc Esp Oftalmol; 2011 Dec; 86(12):407-11. PubMed ID: 22117740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy.
    Lim JW; Kim MU; Shin MC
    Retina; 2010 Oct; 30(9):1465-71. PubMed ID: 20526231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
    Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
    Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
    Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
    Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of intravitreal bevacizumab for idiopathic central serous chorioretinopathy.
    Lim JW; Kim MU
    Graefes Arch Clin Exp Ophthalmol; 2011 Jul; 249(7):969-74. PubMed ID: 21140161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.